These findings suggest that FASN inhibition disrupts key signaling pathways critical for AML cell survival, underscoring the potential for therapeutic strategies combining FASN inhibitors with agents such as PAT, FLT3 inhibitors, or Hedgehog pathway inhibitors. The gene discussed is FASN; the disease is acute myeloid leukemia.